The characteristic t(12;16)(q13;p11) chromosomal translocation, which leads to gene fusion that encodes the FUS-CHOP chimeric protein, is associated with human liposarcomas. The altered expression of FUS-CHOP has been implicated in a characteristic subgroup of human liposarcomas. We have introduced the FUS-CHOP transgene into the mouse genome in which the expression of the transgene is successfully driven by the elongation factor 1a (EF1a) promoter to all tissues. The consequent overexpression of FUS-CHOP results in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-speci®c genes and a concordant block in the dierentiation program. We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high levels of the adipocyte regulatory protein PPARg, whereas it is not expressed in embryonic ®broblasts from these animals following induction to dierentiation toward the adipocyte lineage, indicating that the in vitro system does not really re¯ect the in vivo situation and the developmental defect is downstream of PPARg expression. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1a promoter. This establishes FUS-CHOP overexpression as a key determinant of human liposarcomas and provide the ®rst in vivo evidence for a link between a fusion gene created by a chromosomal translocation and a solid tumor.
The characteristic t(12;16)(q13;p11) chromosomal translocation, which leads to gene fusion that encodes the FUS-CHOP chimeric protein, is associated with human liposarcomas. The altered expression of FUS-CHOP has been implicated in a characteristic subgroup of human liposarcomas. We have introduced the FUS-CHOP transgene into the mouse genome in which the expression of the transgene is successfully driven by the elongation factor 1a (EF1a) promoter to all tissues. The consequent overexpression of FUS-CHOP results in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-speci®c genes and a concordant block in the dierentiation program. We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high levels of the adipocyte regulatory protein PPARg, whereas it is not expressed in embryonic ®broblasts from these animals following induction to dierentiation toward the adipocyte lineage, indicating that the in vitro system does not really re¯ect the in vivo situation and the developmental defect is downstream of PPARg expression. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1a promoter. ThisIntroduction A recurring theme in the molecular pathogenesis of human cancer is the activation of cellular protooncogenes by acquired chromosomal aberrations, the most frequent of which are chromosomal translocations. Characterization of these chromosomal lesions has resulted in the identi®cation of a growing number of candidate oncogenes implicated in the causation of human cancers. Translocations activate cellular oncogenes by one of two general mechanisms: by inducing changes in their regulated expression or by altering their structures to produce mutant proteins . Although gene activation is the result of the chromosomal abnormalities involving Ig and TCR genes in lymphoid malignancies, the most common consequence of chromosome translocations in human cancer (leukemias and solid tumors) is gene fusion. Several translocations in leukemias lead to production of fusion proteins that represent chimeric transcription factors (SaÂ nchez-GarcõÂ a, 1997). The majority of genes activated or generated by chromosomal translocations in human cancer share a common structural composition. These activated or created oncogenes are mainly transcription factors with activation domains linked to DNA binding domains or domains which can interact with proteins which in turn bind DNA (SaÂ nchezGarcõÂ a and . Majority of these genes, activated or created by chromosomal abnormalities, likely play a role in tumor-speci®c cell dierentiation and proliferation controls because of their homology or identity to genes previously identi®ed in other experimental systems that eect development or dierentiation. Perturbations in this orderly process can result in blockades that permit the accumulation of immature proliferating cells or cancer cells.
The link between oncogenesis and transcriptional deregulation has been further strengthened by the recent cloning of the chromosomal abnormalities associated with solid tumors (reviewed by SaÂ nchezGarcõÂ a, 1997). Liposarcoma is the most common soft tissue malignancy in adults, accounting for at least 20% of all sarcomas in this age group (Mack, 1995) . Multiple histologic subtypes of liposarcoma are recognized including well dierentiated, dedierentiated, myxoid, round cell, and pleomorphic. The histologic group is predictive of both the clinical course of the disease and the ultimate prognosis (Chang et al., 1989) . The myxoid/round cell liposarcomas exhibited the characteristic t(12;16)(q13;p11) translocation (Knight et al., 1995) . The molecular characterization of this translocation revealed a fusion between the CHOP gene and a gene called TLS/FUS (Crozat et al., 1993; Rabbitts et al., 1993) , resulting in the RNA-binding domain of TLS/FUS being replaced by the basic leucine zipper domain of CHOP, which confers the ability to form protein dimers (Ron and Habener, 1992; Crozat et al., 1993) . The TLS/FUS gene has also been shown to fuse with the gene for Etslike protein ERG as a result of the translocation t(16;21)(p11;q22) in some patients with acute non-lymphoblastic leukemia (Shimizu et al., 1993; Ichikawa et al., 1994; Panagopoulos et al., 1994 Panagopoulos et al., , 1995 . The portion of TLS/FUS that is present in the TLS/FUS-CHOP and FUS-ERG fusion proteins is similar and this part has been shown to be an autonomous transcriptional activation domain (Prasad et al., 1994; SaÂ nchez-GarcõÂ a and Rabbitts, 1994; Zinszner et al., 1994) . In the FUS-CHOP fusion, transcriptional activation is therefore speci®cally conferred on the chimeric protein by the FUS segment after the translocation event (SaÂ nchez-GarcõÂ a and .
CHOP is a small nuclear protein that avidly forms heterodimers with members of the C/EBP family of transcription factors (Ron and Habener, 1992) . Members of the C/EBP family are known to have an essential role in adipose tissue development (Cao et al., 1991; Samuelsson et al., 1991; Umek et al., 1991; Freytag and Geddes, 1992; Wang et al., 1995; Yeh et al., 1995) and FUS-CHOP blocks dierentiation of adipogenic precursors in tissue culture (Kuroda et al., 1997; Adelmant et al., 1998) . Whereas interference with the normal process of dierentiation may contribute to the oncogenic potential of FUS-CHOP fusion protein, it is a property that they share with the nontransforming germline CHOP gene product (Zinszner et al., 1994; Batchvarova et al., 1995) . CHOP expression is tightly regulated. Under normal conditions the gene is repressed and CHOP mRNA and protein are absent from cells (Fornace et al., 1989; Price and Calderwood, 1992; Carlson et al., 1993; Wang et al., 1996) . In contrast with CHOP, FUS is a constitutively activated gene (Aman et al., 1996) . These observations support a model whereby the FUS-CHOP fusion gene represent a gain-of-function mutation of CHOP that deregulate both gene expression and protein activity. Expression of FUS-CHOP chimeric protein is observed exclusively in a characteristic subgroup of human liposarcomas (Knight et al., 1995) . In vitro, however the transforming eects of FUS-CHOP have been demonstrated in ®broblasts (REF), but curiously not in 3T3-L1 cells under conditions expected to yield oncogenic eects (Zinszner et al., 1994) , suggesting that the function of FUS-CHOP is in¯uenced by the cell environment in vitro.
Thus, elucidation of the eect of FUS-CHOP in vivo is crucial for the understanding of liposarcoma pathogenesis itself, and goes beyond simply clarifying the mechanisms which underlay liposarcoma in FUS-CHOP-associated cancers. In transgenic mice in which FUS-CHOP is ubiquitous expressed, we show that the overexpression of FUS-CHOP results in most of the symptoms of human liposarcomas. We have also demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high levels of the adipocyte regulatory protein PPARg whereas it is not expressed in embryonic ®broblasts from these animals following induction to dierentiation toward the adipocyte lineage, indicating that the in vitro system does not really re¯ect the in vivo situation and the development defect is downstream of PPARg expression. Our results identify the FUS-CHOP as the main mechanism in human liposarcoma and provide the ®rst in vivo evidence for a link between a chimeric protein created by a chromosomal abnormality and a human solid tumor. The transgenic animal model will be an excellent tool in studying the mechanism by which FUS-CHOP induces liposarcomas and for the identi®cation of anti-cancer drugs.
Results

Generation of EF-FUSCHOP transgenic mice
Despite the successful identi®cation of speci®c and consistent genetic events in solid tumors, the nature of the intimate association between the gene fusion and the resulting phenotype is not known. To better understand the role of fusion genes created by chromosomal translocations associated with solid tumors, we have used as a model the FUS-CHOP chimeric gene. We have generated transgenic mice in which FUS-CHOP was expressed from the elongation factor 1a (EF-1a) promoter. The idea of choosing this promoter was based on previous work with this promoter in transgenic mouse technology (Takada et al., 1997) . Transgenic mice carrying the EF-GFP gene were successfully produced, grew normally, showed no obvious anomaly, and the GFP expression was clearly detected at a four-cell stage in the embriogenesis (Takada et al., 1997) . In order to examine the direct consequences of FUS-CHOP expression in vivo, the cDNA of the human FUS-CHOP chimeric protein was cloned downstream the EF-1a promoter (EF-FUSCHOP) to direct expression to all tissues ( Figure  1a ) and injected into C57BL/6 x CBA fertilized eggs. Three founders were obtained: IS58, IS65 and IS72. Only two founder lines, IS58 and IS65, showed germline transmission of the transgene (Table 1) . Transgene expression was observed in both lines and progeny were subsequently bred to the F7 level. Tissue expression of the EF-FUSCHOP transgene was (Figure 1b) . Both expressing lines, showed no preferential expression in fat-tissues. The elongation factor 1a (EF-1a) promoter successfully drove the expression of FUS-CHOP in dierent tissues in the mouse (Figure 1b ). Normal mouse fat cells treated in parallel did not exhibit any expression. Transgenic expression was detected in both male and female mice and similar ®ndings were present in both lines of EF-FUSCHOP transgenic mice.
The FUS-CHOP oncogene expressed from the EF-1a promoter produces adipose tumors in transgenic mice
Cohorts of transgenic mice were generated to analyse the eect of the eect of the FUS-CHOP fusion gene (Table 1) . Uniformly, male and female EF-FUSCHOP transgenic mice showed the same symptoms beginning as early as 8 weeks of age with increasing signs over time leading to death in 100% of the mice by 12 months of age (Table 1 ). The founder mice were male and female and develop clinical disease similar to that of other transgenic mice. All FUSCHOP transgenic mice died from tumors by 14 ± 18 months of age. The survival was similar in the two founder lines. No tumors were observed in a cohort consisting of an equal number of nontransgenic littermates. Animals frequently experienced tachypnea requiring euthanasia. At the time of autopsy, these animals had developed palpable masses involving the adipose tissues, which, upon dissection, revealed white adipose pads ®ve-to 100-fold normal size. Tumor in®ltration of non-adipose tissues was not visible and was con®rmed microscopically. All these animals had visible masses as early as 8 ± 10 weeks. In addition, some animals not included in Table 1 did not develop palpable masses but showed microscopic tumor upon dissection when they were sacri®ced at 10 weeks of age. This examination is consistent with adipose tissue disease. However, no tumors of other tissues were found in these EF-FUSCHOP transgenic mice, despite widespread activity of the EF-1a promoter.
FUS-CHOP transgenic mice specifically develop liposarcomas
In human pathology the FUS-CHOP chimeric product is associated with liposarcomas (Crozat et al., 1993; Rabbitts et al., 1993; Knight et al., 1995) . Therefore, we next de®ned the adipose tissue disease generated in our EF-FUS-CHOP transgenic mice. Detailed analysis of the tumor cells in the EF-FUS-CHOP transgenic mice established the diagnosis as malignant liposarcomas. Haematoxilin/Eosin staining showed that the tumor cells had an adipoblast morphology (Figures 2  and 3 ). Histologically, all tumors were diuse liposarcomas composed of medium to large cells with round nuclei and were very similar to human liposarcomas (see http://www.dml.georgetown.edu/ webpath/MUSCHTML/MUSCIDX.html). The tumors were classi®ed according to histological criteria as high grade myxoid/round cell (30 mice), high grade, pleomorphic, and myxoid areas (14 mice), high grade, mixed pleomorphic/round cell (six mice), intermediate grade, myxoid4round cell (four mice), and intermediate grade, round cell4myxoid (three mice). Death in transgenic animals was the result of malignant liposarcomas con®rmed by autopsy and histologic examination, except ®ve animals too decomposed for analysis. The histopathological analyses of the white adipose depots in both EF-FUSCHOP transgenic lines revealed multiple abnormalities. Some contained only modest morphological changes consisting primarily of an increase in nuclear size and number per microscopic ®eld, but the white adipose tissue (WAT) of majority of the mice had a much more hypercellular appearance and contained scattered cells with enlarged pleomorphic nuclei. In general, the animals with large sarcomas had relatively small WAT depots. In these white fat pads the normal architecture of the tissue was largely or completely disrupted by the extensive proliferation of white adipocytes. Virtually all of the white adipocytes in these dysplastic depots had some degree of cytologic atypia such as cellular or nuclear enlargement and pleomorphism (Figures 2 and 3) . Nests of compact anaplastic liposarcoma cells were often scattered throughout these depots. All WAT deposits in these animals were generally aected at least with abnormal adipocytes and, in some cases, foci of sarcomas were clearly discernible. Pathological changes were not observed in the brown adipose tissue (BAT) of these transgenic mice. Histopathological examination of the other organs of these animals (spleen, pancreas, liver, thymus, kidney, brain, heart, skeletal muscle, bone, tendons, cartilage, lung, salivary gland) showed no other abnormalities, with the exception of skeletal abnormalities. We did not ®nd focus of tumor cells in any of these organs. The tumors were invariable found in the WAT depots, usually multifocally in any WAT depot.
To test the malignant nature of cells from the EF-FUSCHOP transgenic mice, 1610 6 cells were injected subcutaneously into 40 day old nude mice. Forty mice injected developed progressively growing tumors within 3 ± 7 weeks of transplantation. In contrast, transfer of 30-fold greater number of cells from 6-week-old nontransgenic to nude recipients resulted in no tumors. The transplanted cells developed into the same kind of tumor as de®ned by histological analysis. Furthermore, the origin of liposarcoma cells from donor mice was con®rmed by PCR analysis revealing the presence of the FUS-CHOP gene product. These data de®ne the tumors generated in the EF-FUSCHOP transgenic mice as malignant liposarcomas. Therefore, our mouse model reproduces the same phenotype with which this fusion gene is associated in human pathology and identify the FUS-CHOP as the main mechanism in human liposarcoma. This result validate this mouse model as ideal to study the biology of the FUS-CHOP oncogene. 
Expression of adipocyte-specific genes in EF-FUSCHOP liposarcomas
While the precise nature of the developmental defect in liposarcoma is not yet clear, it is likely these defects ultimately lead to the inactivation or antagonism of one or more adipocyte transcriptional regulatory proteins. Members of both the C/EBP and PPAR transcription families play central and complementary roles in adipogenesis in murine models (Hwang et al., 1997) . They are expressed at speci®c times during adipogenesis in a manner that is consistent with a distinct regulatory role of each protein. The precise mechanism whereby FUS-CHOP contributes to dierentiation arrest, however, remains to be elucidated. Therefore, we next examined the expression of adipocyte-speci®c genes in order to de®ne the level at which the dierentiation is blocked in FUS-CHOP liposarcomas. Moreover, identi®cation of lipoblasts using markers of adipocyte expression is of value in the dierential diagnosis of benign and malignant adipose tissue tumors and in distinguishing liposarcomas from other malignant mesenchymal and epithelial neoplasms, some of which contain cells that morphologically resemble adipoblasts (Benneth et al., 1995; Tontonoz et al., 1997) . The nuclear receptor peroxisome proliferative-activated receptor g (PPARg) plays a central role in the process of adipocyte dierentiation. This receptor and its heterodimeric partner retinoid X receptor a (RXRa) form a DNAbinding complex that regulates transcription of adipocyte-speci®c genes (Kliewer et al., 1992) . We examine the expression of PPARg in FUS-CHOP liposarcomas by Northern blot analysis (Figure 4) . Surprisingly, despite their block in dierentiation each liposarcoma examined was found to express signi®cant levels of PPAR-g RNA, comparable to that of normal fat (Figure 4 ). These FUS-CHOP liposarcomas also expressed c/EBPb, d and a and aP2 (data not shown). These results suggest that liposarcomas in FUS-CHOP transgenic mice have been transformed at a point in the dierentiation process after induction of PPARg expression. Moreover, PPARg is not expressed in any other type of soft tissue sarcoma (Tontonoz et al., 1997) and can be considered a sensitive marker for distinguishing liposarcoma from other histologic types of soft tissue sarcoma.
Embryonic fibroblasts from FUSCHOP mice could not differentiate into adipocytes
To demonstrate that this phenotype is not a secondary eect of systemic growth defects, but rather the primary eect of the presence of FUS-CHOP in adipose tissues and to investigate the dierence in the results obtained from the present analysis of FUS-CHOP transgenic mice and previous in vitro culture systems (Zinszner et al., 1994; Kuroda et al., 1997; Figure 2 Histologic appearance of a liposarcoma arising in the region of the testis. Histological analysis was performed when the mice were moribund. The adipose tissue from EF-FUSCHOP transgenic mice that developed an liposarcoma in the region of the testis shows the eacement of the normal fat architecture (a ± c) compared to control mice (d). At high magni®cation, the presence of the lipoblasts are visible in this liposarcoma which correspond to a high grade myxoid/round cell type. Although the liposarcoma disease in EF-FUSCHOP transgenic mice was very similar, the level of adipoblast in®ltration in the two dierent EF-FUSCHOP transgenic lines revealed by histological analysis was not identical. Similar results were found in multiple sections from EF-FUSCHOP transgenic and nontransgenic mice. The original magni®cation is 610 for (a), 620 for (b), 660 for (c) and (d) Adelmant et al., 1998) , we prepared primary embryonic ®broblasts from each line and examined their dierentiation properties, since cell lines frequently used for in vitro adipocyte dierentiation such as 3T3-L1 preadipose cells are derived from embyronic ®broblasts.
These cell lines can dierentiate into adipocytes in the presence of MIX, DES, INS and FBS (standard dierentiation induction medium) (Hwang et al., 1997) . The embryonic ®broblasts from each line were cultured to con¯uent and then treated with the standard dierentiation induction medium. As shown in Figure 5a , embryonic ®broblasts from wild-type dierentiated into adipocytes and accumulated many lipid droplets in response to hormonal stimulants. In contrast, FUS-CHOP embryonic ®broblasts can hardly dierentiate into adipogenic cells and accumulate very few lipid droplets. Oil-Red-O staining demonstrated clear dierences in adipocyte phenotype (Figure 5a ).
There are speci®c markers genes for each stage of adipocyte dierentiation. For example, LPL is expressed at the pre-adipocyte stage and is one of the earliest markers of dierentiation, while aP2 is expressed at the immature adipocyte stage, and adipsin at the mature stage (Ailhaud et al., 1992) . These ®ndings were based mainly on in vitro experiments using a 3T3-L1 pre-adipocyte dierentiation system. Thus, we next examined the expression of adipocytespeci®c genes during the course of adipocyte dierentiation. Adipocyte dierentiation of wild-type embryonic ®broblasts (MEF) accompanied the expression of all the adipocyte markers examined, which is indicative of a completely mature state (Figure 5b ). In contrast, MEFs from transgenic FUS-CHOP mice only expressed the earliest markers of dierentiation, which corresponds to preadipocytes. As shown in Figure 5b, PPARg was also expressed in the wild-type MEFs but not in FUS-CHOP MEFs during the course of dierentiation. Taken together, these results show that adipocyte dierentiation was blocked in cultured FUS-CHOP embryonic ®broblasts treated with adipogenic hormons. However, in vivo, these transcription factors were expressed normally in liposarcoma tissues indicating that FUS-CHOP blocks the dierentiation process after induction of PPARg expression. Clearly there is a discrepancy between the in vivo and the in vitro experiments: PPARg is expressed in the tumors of the transgenic animals whereas it is not expressed in embryonic ®broblasts from these animals following induction to dierentiation toward the adipocyte lineage, indicating that the in vitro system does not really re¯ect the in vivo situation.
Other abnormalities in FUS-CHOP transgenic mice: skeletal defects
As we have mentioned previously, the examination of the other organs in the FUS-CHOP transgenic mice showed no other abnormalities, with the exception of skeletal defects. All EF1-FUSCHOP transgenic mice exhibited skeletal abnormalities of variable severity. Skeletal defects include scoliosis and curvature. We did not detect overgrowth of long bones and vertebrae. We used nuclear magnetic resonance (NMR) to de®ne the presence or degree of pathological changes in the spine of these transgenic animals. Lesions extended over the entire spine, however, the larger lesions were predominantly present in the thoracic and upper lumbar regions. Axial and transversal scans of the dorsolumbar spine were obtained. The imaging parameters (®eld-of-view, slice thickness, interslice gap, number of excitations and matrix size) and scan levels were identical for each pair of sequences. At two selected levels, L4/5 and L5/ S1, various structures were independently graded by two observers. Skeletons of EF1-FUSCHOP transgenic mice (n=20) and age-matched controls (n=10) ranging from 2 ± 8 months of age were examined. Every FUS-CHOP skeleton exhibited moderate to severe scoliosis, primarily in the dorsal and upper b Figure 5 (a) Adipogenic dierentiation from primary embryonic ®broblasts. Primary embryonic ®broblasts from each transgenic line were cultured in the presence of standard dierentiation induction medium (containing 0.5 mM MIX, 1 mM DEX, 5 mg/ml INS and 10% FBS). After 8 days of dierentiation, cells were observed by light microscopy with Oil-Red-O staining. Cells from nontransgenic (left) and TG-IS65 (right) are shown. The original magni®cation is 620. This experiment was repeated four times using cells prepared from both transgenic lines and from dierent embryos and similar results were obtained. (b) Northern blot analysis of primary embryonic ®broblasts during adipogenic dierentiation. Primary embryonic ®broblasts from each FUSCHOP transgenic line were dierentiated in the presence of the hormonal stimulants described in Materials and methods. RNA was extracted from the cells at day 0, 2, 5 and 8 of dierentiation. Ten mg of total RNA were subjected to Northern blot analysis using the probes as indicated A Liposarcomas in transgenic mice by FUS/TLS-CHOP J Pe Â rez-Losada et al lumbar spine. This pathology resulted in reduction of thoracic cavity volume ( Figure 6 ). No abnormalities in bone histology can account for the deformities observed in the skeletal. The curvature of vertebra is consistent with poorly regulated turnover of the growth plates to trabecular bone, allowing external pressures on growth plates to unduly aect bone shape.
Discussion
Chromosomal translocations entail the generation of gene fusions in solid mesenquimal tumors (reviewed by SaÂ nchez-GarcõÂ a, 1997). Despite the successful identi®cation of these speci®c and consistent genetic events, the nature of the intimate association between the gene fusion and the resulting phenotype is pending to understand. In this report we have investigated the issue of lineage speci®city and oncogenic properties of FUS-CHOP in transgenic mouse models.
The role of FUS-CHOP in the genesis of liposarcomas
In order to elucidate the eect of FUS-CHOP in liposarcomas we have introduced the FUS-CHOP transgene into the mouse genome. The consequent overexpression of FUS-CHOP resulted in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-speci®c genes and a concordant block in the dierentiation program. We have also demonstrated here that liposarcomas in FUS-CHOP trangenic mice, like most human liposarcomas, express high levels of the adipocyte regulatory protein PPARg, suggesting that the dierentiation block is downstream of PPARg expression. Moreover, these adipocyte-speci®c genes are only expressed by lipoblasts in all types of liposarcomas in humans (Benneth et al., 1995; Tontonoz et al., 1997) , demonstrating that the malignant tumors in the FUSCHOP transgenic mice were liposarcomas. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1a promoter. The powerful tissuespeci®c transforming activities exhibited by FUS-CHOP re¯ect the particular sensitivity of certain target cells to their action. The nature of the cellular precursors or FUS-CHOP target cell in human liposarcomas is not known. To the extent that it is capable of dierentiation to an adipocytic cell, it is likely to be a mesenchymal precursor of fat (Figure 7 ). These considerations underscore the relevance of relationship between FUS-CHOP and the cell environment.
In both EF-FUSCHOP transgenic lines, in which there is uniform expression of the transgene, multiple palpable adipose tumors synchronously arise. Their simultaneous occurrence, extensively involving all adipose areas, is consistent with the diuse, policlonal origin of these tumors. Moreover, these histologically malignant tumors readily grow when transplanted into nude mice. Together these results strongly support that the expression of the FUS-CHOP oncogene does not require further complementary genetic changes in order to transform the adipose target cell. The apparent single-step action of the FUS-CHOP contrasts with previous experience with transgenic mice bearing other oncogenes (Adams et al., 1985; Leder et al., 1986; Quaife et al., 1987; Ruther et al., 1987; Sinn et al., 1987) . However, if one considers the combined eects of FUS-CHOP on dierentiation and proliferation controls, it seems reasonable to think that the single chromosome abnormality that leads to the generation of this protein may be all that is needed for the liposarcoma target cells to become transformed. Similar eects have been mentioned for BCR-ABLP 190 (Castellanos et al., 1997) and PML-RAR (Altabef et al., 1996) . Both oncoproteins are able to generate a full malignant phenotype by blocking the dierentiation program of the tumor-target cell. Thus, as it has been proposed (SaÂ nchez-GarcõÂ a, 1997), the products created by chromosomal abnormalities may be all that is required for the tumor target cells to become fully transformed. Resembling the human situation, we have not observed instances of metastases in the transgenic lines. However, the one-step acquisition of the malignant phenotype does not rule out the possibility of further progression of these malignancies. The fact that FUS-CHOP transgenic mice develop speci®cally liposarcomas establishes FUS-CHOP overexpression as a key determinant of human liposarcomas and provide the ®rst in vivo evidence for a link between a fusion (Hwang et al., 1997) . The transgenic model of constitutive FUS-CHOP expression oers a unique opportunity to dissect the molecular mechanisms involved in liposarcoma disease. In these mice, FUS-CHOP may be directly block the adipocytic development as has been shown in vitro. In the in vitro study of adipocyte dierentiation using primary embryonic ®broblasts derived from transgenic FUS-CHOP mice, the expression of both PPARg and c/EBPa was severely reduced to almost undetectable levels, and the expression of several adipogenic marker genes was also impaired. However, in vivo, these transcription factors were expressed normally in liposarcoma tissues indicating that the dierentiation block was taken place after induction of PPARg expression (Figure 7) . Clearly there is a discrepancy between the in vivo and the in vitro experiments. Similar phenotype has been described in mice lacking c/EBPb and d (Tanaka et al., 1997) . With the restricted number of stimuli in vitro, PPARg and c/EBPa are induced according to a proposed cascade of transcription factors, but in vivo, PPARg and c/EBPa may be induced by other transcription factors. Thus, it is important to identify such transcription factors for alternative pathways that may lead to PPARg or c/EBPa expression by FUS-CHOP. Recently, it has been demonstrated that the induction of PPARg does not always require c/EBPb and d, and co-expression of c/EBPa and PPARg is not sucient for complete adipocyte dierentiation (Tanaka et al., 1997) . Although, in vitro it is possible that FUS-CHOP and its normal counterpart CHOP inhibit dierentiation by interfering with the activation of transcription by C/EBP family members. In vivo, however, it seems that FUS-CHOP is not able to sequester C/EBPs. Alternatively, FUS-CHOP may modify the C/EBP response by altering the subset of DNA-binding sites through which C/EBPs activate transcription. Further studies to identify the target genes and proteins that are regulated by FUS-CHOP using our transgenic mice will produce a clearer picture of the development defect in liposarcoma (Figure 7) . Future experiments breeding these mice with adipocyte-speci®c gene knockout mice will further identify factors that play roles in the developmental defect identi®ed in liposarcomas of FUS-CHOP transgenic mice.
Possible relevance to human solid tumors
In the present report, we have taken advantage from the EF-1a promoter to express the FUS-CHOP oncogene in transgenic mice. A number of conclusions can be made from our experiments which can be relevant to understanding the molecular basis of the eect of other gene fusions created by chromosomal abnormalities in human malignant sarcomas. First, despite the activity of the promoter in a wide range of tissues, transgenic mice expressing FUS-CHOP from this promoter speci®cally and systematically develop liposarcomas, indicating the ecacy of this promoter for studying the role of speci®c chromosome abnormalities in tumor development. This ®nding indicates that FUS-CHOP may preferentially exert oncogenic eects in the mesenquimal compartment and the importance of the target cell for transgenic models of human cancer. Second, the FUS-CHOP fusion gene is important for tumor development, indicating that FUS-CHOP expression is the prime event initiating liposarcomas. Third, the phenotype of these tumors is very close to the phenotype seen in patients with liposarcomas, mimicking the eect of the chromosomal translocation. These animals will be an ideal model to study the function of FUS-CHOP oncogene in malignant transformation and develop new speci®c anti-cancer therapies. Moreover, this new mouse model provide a new framework for viewing the cellular and molecular mechanisms that underlie the heterogeneity seen in human solid tumors; particularly the impact that fusion gene expression has on the development program of normal mesenquimal stem cells. These studies will contribute to understanding the fundamental diversity of the dierent diseases that are uni®ed under the common heading of malignant mesenquimal tumors.
Materials and methods
The generation and screening of transgenic mice PCR ampli®cation of the FUS-CHOP cDNA was done to facilitate cloning by adding restriction enzymes using primers that hybridize to the 5' and 3' ends of the cDNA and amplify a region including the entire coding region of the gene. The 1380-base pair product was cloned into the M13mp19 vector, added to 3' end an in-frame sequence coding for a MYC-tag recognized for the 9E10 antibody, and sequenced. The cDNA was cloned into a plasmid, pEF-BOS, containing sequences of the EF1-a promoter, followed by a polylinker region linked to the poly(A) + adenylation signal from human G-CSF cDNA as described (Mizushima and Nagata, 1990) . A linear DNA fragment for microinjection was obtained by HindIII digestion and injected by the INIA Transgenic Facility into CBA x C57BL/6J fertilized eggs. Transgenic founders were identi®ed by Southern blot analysis through detection of the novel EF-FUSCHOP construct from samples of DNA extracted from tails.
Tumor histology
FUS-CHOP transgenic mice were sacri®ced when they exhibited distress and subjected to standard necropsy. All major organs were closely examined under the dissecting microscope, and samples of each organ were processed into paran, sectioned and examined histologically. Tumor specimens from the transgenic mice were ®xed into 10% formalin overnight, then processed, embedded in paran, and 6 mm sections were stained with hematocylin and eosin and photographed. All tissue samples were taken from homogenous and viable portions of the resected sample by the pathologist and ®xed within 2 ± 5 min of excision. Hematoxylin-and eosin-stained sections of each soft tissue sarcoma were reviewed by a single pathologist (TF) and classi®ed according to histologic type and grade. Histological classi®cation was based solely on morphologic pattern recognition using conventional diagnostic criteria.
Cell transplantation to nude mice
Liposarcoma tumors were dispersed in Dulbecco's modi®ed Eagle's medium containing 5% fetal calf serum by mechanical shearing onto a large mesh grid and injected subcutaneously into 40-day-old nude mice. Approximately 10 6 cells were injected at each site. Mice were monitored once a week and were killed for histopathologic studies and collection of tissues for DNA analyses when moribund.
Preparation of primary embryonic fibroblasts and induction of adipogenic differentiation
Primary embryonic ®broblasts were harvested from 14.5 d.p.c. embryos. Cells were cultured at 378C in Dubelcos-modi®ed Eagle's medium (DMEM; Boehringer Ingelheim) supplemented with 10% heat-inactivated FBS (GIBCO/BRL). Cells were plated to 24-well or 60 mm plastic dishes and propagated to con¯uence. Two days later, medium was replaced with standard dierentiation induction medium containing 0.5 mM MIX (Sigma), 1 mM DEX (Sigma), 5 mg/ ml INS (Sigma) and 10% FBS (GIBCO/BRL). This medium was removed every other day. After 8 days, the appearance of cytoplasmic lipid accumulation was observed by microscopy with Oil-Red-O staining. The Oil-Red-O staining was performed as follows: cells were washed with phosphatebuered saline (PBS), and then stained with 60% ®ltered OilRed-O stock solution (0.15 g of Oil-Red-O (Sigma) in 50 ml of isopropanol) for 30 min at 378C. Cells were washed ®rst with 60% isopropanol and then brie¯y with water and visualized. To prepare RNA for Northern blotting, cells were harvested at days 0, 2, 5 and 8 of dierentiation.
Northern blot analysis
Total RNA was isolated from liposarcomas and epidydimal fat pad of adult mice and dierentiating ®broblasts. Ten mg of each RNA sample were glyoxylated and fractionated in 1.4% agarose gels in 10 mM Na 2 HPO 4 buer (pH 7.0). After electrophoresis, the gel was blotted onto Hybond-N (Amersham), UV-cross-linked, and hybridized to 32 P-labeled probes. The probes were labeled by random priming using the Oligolabelling system (Pharmacia) and a-32 PdCTP (Amersham). cDNAs used as a probe were as follows: murine c/ EBPa, b, d (which were prepared from genomic DNA), adipsin, aP2, LPL, PPARg, and b-actin (which were ampli®ed by PCR from adipose tissue cDNA using speci®c primers).
Western blot analysis
Single cell suspensions coming from dierent tissue samples were analysed by immunoblotting procedures as essentially as described (Castellanos et al., 1997) . Lysates were run on a 10% SDS ± PAGE gel and transferred to a PVDF membrane. After blocking, the membrane was probed with c-Myc (9E10) mouse monoclonal antibody (Santa Cruz), which is speci®c for human c-Myc (amino acids 408 ± 439). Reactive bands were detected with an ECL system (Amersham).
Nuclear magnetic resonance (NMR)
Axial and transversal scans of the dorsolumbar spine were obtained from FUS-CHOP transgenic and age-matched control mice using standard techniques. The imaging parameters (®eld-of-view, slice thickness, interslice gap, number of excitations and matrix size) and scan levels were identical for each pair of sequences. At two selected levels, D4/5 and D12/L1, various structures were independently graded by two observers (B BanÄ ares-Gonzalez and J Calabia del Campo).
